research

Glaucoma Research Articles

FitEyes provides a collection of carefully selected, edited and well-organized glaucoma research articles. You can find them in this section. See the menu on the side for a list of all articles.

About FitEyes.com

FitEyes.com is currently the largest eye pressure research and glaucoma support community in the world. FitEyes also features information regarding general well-being, healthy lifestyle, nutrition, general fitness, and, in particular, overall eye health. This information includes, but is not limited to, articles, editorial content, blogs, published research, and members’ reviews, postings and discussions.

Conducting research on relaxation techniques to lower eye pressure

Submitted by Jerrold Ehrlich on Fri, 01/28/2011 - 1:35pm

I am an attorney and my spouse is a glaucoma patient. In the past I have volunteered some of my time to help FitEyes look into questions related to research projects and other activities related to the non-medical treatment of elevated 
intraocular pressure. I would like to share my feedback in two areas:

  • our outstanding questions
  • what we know so far.

Here are some of the outstanding questions that apply directly to the project presently under discussion, which is related to using a relaxation technique to lower intraocular pressure.

Eye pressure question - how do I go about testing this further with my tonometer?

Submitted by Thomas Hirsz on Sat, 09/04/2010 - 7:59am

My elevated intraocular pressure in the evening seems to decrease when I lie down and read. However this could be due to other factors such as the eye drops kicking in. How would I go about testing this further?

Nitric Oxide compound lowers eye pressure more than glaucoma drugs like Xalatan alone

Submitted by dave on Mon, 04/26/2010 - 8:03pm

 A Novel Nitric Oxide Releasing Prostaglandin Analog, NCX 125, Reduces Intraocular Pressure in Rabbit, Dog, and Primate Models of Glaucoma

 

Abstract

 

Purpose: Nitric oxide (NO) is involved in a variety of physiological processes including ocular aqueous humor dynamics by targeting mechanisms that are complementary to those of prostaglandins. Here, we have characterized a newly synthesized compound, NCX 125, comprising latanoprost acid and NO-donating moieties.

Methods: NCX 125 was synthesized and tested in vitro for its ability to release functionally active NO and then compared with core latanoprost for its intraocular pressure (IOP)-lowering effects in rabbit, dog, and nonhuman primate models of glaucoma.

Results: NCX 125 elicited cGMP formation (EC50 = 3.8 ± 1.0 μM) in PC12 cells and exerted NO-dependent iNOS inhibition (IC50 = 55 ± 11 μM) in RAW 264.7 macrophages. NCX 125 lowered IOP to a greater extent compared with equimolar latanoprost in: (a) rabbit model of transient ocular hypertension (0.030% latanoprost, not effective; 0.039% NCX 125, ∆max = −10.6 ± 2.3 mm Hg), (b) ocular hypertensive glaucomatous dogs (0.030% latanoprost, ∆max= −6.7 ± 1.2 mm Hg; 0.039% NCX 125, ∆max = −9.1 ± 3.1 mm Hg), and (c) laser-induced ocular hypertensive non-human primates (0.10% latanoprost, ∆max = −11.9 ± 3.7 mm Hg, 0.13% NCX 125, ∆max = −16.7 ± 2.2 mm Hg). In pharmacokinetic studies, NCX 125 and latanoprost resulted in similar latanoprost-free acid exposure in anterior segment ocular tissues.

Conclusions: NCX 125, a compound targeting 2 different mechanisms, is endowed with potent ocular hypotensive effects. This may lead to potential new perspectives in the treatment of patients at risk of glaucoma.

 

Meeting To Discuss Non-medical Management of Eye Pressure and Self-Tonometry

Submitted by dave on Sat, 05/30/2009 - 1:59pm

This year the World Glaucoma Congress (WGC) is taking place in the United States (Boston, MA) from July 8th to 11th. Dr. Ritch will be there, as will Marcel and I.

I believe all of you know, or know of, Dr. Ritch. Marcel is a key founder of the International Society for Self-Tonometry (ISST), of which Dr. Ritch is Honorary Chairman. Marcel is a driving force behind getting me and several other self-tonometrists together in Boston.

No disease in the brain of a 115-year-old woman

Submitted by dave on Fri, 05/29/2009 - 3:28pm

Are there limits to the duration of high quality of life? Are there limits to healthy life for a human brain? [These questions are relevalant for vision as well as cognitive health because the optic nerve is part of the central nervous system.]

Molecular pathology of age-related macular degeneration

Submitted by dave on Fri, 05/29/2009 - 11:20am

Age-related macular degeneration (AMD) is a leading cause of irreversible blindness in the world. Although the etiology and pathogenesis of AMD remain largely unclear, a complex interaction of genetic and environmental factors is thought to exist. AMD pathology is characterized by degeneration involving the retinal photoreceptors, retinal pigment epithelium, and Bruch’s membrane, as well as, in some cases, alterations in choroidal capillaries.

Pages

Subscribe to FitEyes.com RSS Feed Subscribe to research